Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors

Genes and Development

Volumn 26, Issue 12, 2012, Pages 1326-1338

  Xiao, Mengtao ^a,b   Yang, Hui ^a,b   Xu, Wei ^b   Ma, Shenghong ^a,b   Lin, Huaipeng ^a,b   Zhu, Honguang ^a   Liu, Lixia ^c   Liu, Ying ^a   Yang, Chen ^c   Xu, Yanhui ^a   Zhao, Shimin ^b   Ye, Dan ^a   Xiong, Yue ^a,b,d   Guan, Kun Liang ^a,e  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c INSTITUTE OF PLANT PHYSIOLOGY AND ECOLOGY   (China)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

KG dependent dioxygenases; DNA methylation; FH; Histone methylation; Metabolites; SDH

Indexed keywords

ALPHA KETOGLUTARATE DEPENDENT DIOXYGENASE; COLLAGEN PROLYL 4 HYDROXYLASE; DIOXYGENASE; FUMARATE HYDRATASE; FUMARIC ACID; HISTONE DEMETHYLASE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; SUCCINATE DEHYDROGENASE; SUCCINIC ACID; UNCLASSIFIED DRUG;

ARTICLE; CELL LEVEL; COMPETITIVE INHIBITION; CONTROLLED STUDY; DEMETHYLATION; ENZYME INHIBITION; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; HYDROXYLATION; PRIORITY JOURNAL; PROTEIN CONTENT;

ANIMALS; BIOCATALYSIS; CELLS, CULTURED; DIOXYGENASES; DNA METHYLATION; ENDOSTATINS; FUMARATE HYDRATASE; FUMARATES; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; GENOME, HUMAN; HEK293 CELLS; HISTONE DEMETHYLASES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KETOGLUTARIC ACIDS; MICE; MODELS, BIOLOGICAL; MUTATION; SUCCINATE DEHYDROGENASE; SUCCINIC ACID; TUMOR SUPPRESSOR PROTEINS;

EID: 84862632865     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.191056.112     Document Type: Article

References (49)

1. Adam J, Hatipoglu E, O'Flaherty L, Ternette N, Sahgal N, Lockstone H, Baban D, Nye E, Stamp GW, Wolhuter K, et al. 2011. Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: Roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell 20: 524-537.
2. Alam NA, Olpin S, Rowan A, Kelsell D, Leigh IM, Tomlinson IP, Weaver T. 2005. Missense mutations in fumarate hydratase in multiple cutaneous and uterine leiomyomatosis and renal cell cancer. J Mol Diagn 7: 437-443.
3. Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, Pollock R, O'Donnell P, Grigoriadis A, Diss T, et al. 2011. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol 224: 306-308.
4. Astuti D, Latif F, Dallol A, Dahia PL, Douglas F, George E, SkÖldberg F, Husebye ES, Eng C, Maher ER. 2001. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 69: 49-54.
5. Bardella C, Pollard PJ, Tomlinson I. 2011. SDH mutations in cancer. Biochim Biophys Acta 1807: 1432-1443.
6. Bayley JP, Launonen V, Tomlinson IP. 2008. The FH mutation database: An online database of fumarate hydratase mutations involved in the MCUL (HLRCC) tumor syndrome and congenital fumarase deficiency. BMC Med Genet 9: 20. doi: 10.1186/1471-2350-9-20.
7. Bayley JP, Kunst HP, Cascon A, Sampietro ML, Gaal J, Korpershoek E, Hinojar-Gutierrez A, Timmers HJ, Hoefsloot LH, Hermsen MA, et al. 2010. SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. Lancet Oncol 11: 366-372.
8. Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A, van der Mey A, Taschner PE, Rubinstein WS, Myers EN, et al. 2000. Mutations in SDHD,a mitochondrial complex II gene, in hereditary paraganglioma. Science 287: 848-851.
9. Bennett BD, Kimball EH, Gao M, Osterhout R, Van Dien SJ, Rabinowitz JD. 2009. Absolute metabolite concentrations and implied enzyme active site occupancy in Escherichia coli. Nat Chem Biol 5: 593-599.
10. Chowdhury R, Yeoh KK, Tian YM, Hillringhaus L, Bagg EA, Rose NR, Leung IK, Li XS, Woon EC, Yang M, et al. 2011. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep 12: 463-469.
11. Damato S, Alorjani M, Bonar F, McCarthy SW, Cannon SR, O'Donnell P, Tirabosco R, Amary MF, Flanagan AM. 2012. IDH1 mutations are not found in cartilaginous tumours other than central and periosteal chondrosarcomas and en-chondromas. Histopathology 60: 363-365.
12. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, et al. 2009. Cancer-associated IDH1 mutations produce 2-hydroxygluta-rate. Nature 462: 739-744.
13. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, et al. 2001. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107: 43-54.
14. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, et al. 2010. Leukemic IDH1 and IDH2 mutations result in a hyper-methylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18: 553-567.
15. Hao HX, Khalimonchuk O, Schraders M, Dephoure N, Bayley JP, Kunst H, Devilee P, Cremers CW, Schiffman JD, Bentz BG, et al. 2009. SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science 325: 1139-1142.
16. Hausinger RP. 2004. FeII/a-ketoglutarate-dependent hydroxylases and related enzymes. Crit Rev Biochem Mol Biol 39: 21-68.
17. He YF, Li BZ, Li Z, Liu P, Wang Y, Tang Q, Ding J, Jia Y, Chen Z, Li L, et al. 2011. Tet-mediated formation of 5-carboxylcyto-sine and its excision by TDG in mammalian DNA. Science 333: 1303-1307.
18. Hemerly JP, Bastos AU, Cerutti JM. 2010. Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas. Eur J Endocrinol 163: 747-755.
19. Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, Chung YL, Merino M, Trepel J, Zbar B, Toro J, et al. 2005. HIF over-expression correlates with biallelic loss of fumarate hydra-tase in renal cancer: Novel role of fumarate in regulation of HIF stability. Cancer Cell 8: 143-153.
20. Ito S, D'Alessio AC, Taranova OV, Hong K, Sowers LC, Zhang Y. 2010. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 466: 1129-1133.
21. Ito S, Shen L, Dai Q, Wu SC, Collins LB, Swenberg JA, He C, Zhang Y. 2011. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 333: 1300-1303.
22. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, Kaelin WG. 2001. HIF1a targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing. Science 292: 464-468.
23. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, von Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, et al. 2001. Targeting of HIF-a to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxyl-ation. Science 292: 468-472.
24. Kaelin WG. 2009. SDH5 mutations and familial paragan-glioma: Somewhere Warburg is smiling. Cancer Cell 16: 180-182.
25. King A, Selak MA, Gottlieb E. 2006. Succinate dehydrogenase and fumarate hydratase: Linking mitochondrial dysfunction and cancer. Oncogene 25: 4675-4682.
26. Krivtsov AV, Feng Z, Lemieux ME, Faber J, Vempati S, Sinha AU, Xia X, Jesneck J, Bracken AP, Silverman LB, et al. 2008. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 14: 355-368.
27. Ling TS, Shi RH, Zhang GX, Zhu H, Yu LZ, Ding XF. 2005. Common single nucleotide polymorphism of hypoxia-induc-ible factor-1α and its impact on the clinicopathological features of esophageal squamous cell carcinoma. Chin J Dig Dis 6: 155-158.
28. Loenarz C, Schofield CJ. 2008. Expanding chemical biology of 2-oxoglutarate oxygenases. Nat Chem Biol 4: 152-156.
29. Lorsbach RB, Moore J, Mathew S, Raimondi SC, Mukatira ST, Downing JR. 2003. TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia 17: 637-641.
30. MacKenzie ED, Selak MA, Tennant DA, Payne LJ, Crosby S, Frederiksen CM, Watson DG, Gottlieb E. 2007. Cell-permeating α-ketoglutarate derivatives alleviate pseudohypoxia in succinate dehydrogenase-deficient cells. Mol Cell Biol 27: 3282-3289.
31. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, Koboldt DC, Fulton RS, Delehaunty KD, McGrath SD, et al. 2009. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361: 1058-1066.
32. Murugan AK, Bojdani E, Xing M. 2010. Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. Biochem Biophys Res Commun 393: 555-559.
33. Mussini E, Hutton JJ Jr, Udenfriend S. 1967. Collagen proline hydroxylase in wound healing, granuloma formation, scurvy, and growth. Science 157: 927-929.
34. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, et al. 2010. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17: 510-522.
35. Oermann EK, Wu J, Guan KL, Xiong Y. 2012. Alterations of metabolic genes and metabolites in cancer. Semin Cell Dev Biol. doi: 10.1016/j.semcdb.2012.01.013.
36. Ooi A, Wong JC, Petillo D, Roossien D, Perrier-Trudova V, Whitten D, Min BW, Tan MH, Zhang Z, Yang XJ, et al. 2011. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell 20: 511-523.
37. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et al. 2008. An integrated genomic analysis of human glioblastoma multi-forme. Science 321: 1807-1812.
38. Pollard PJ, Brière JJ, Alam NA, Barwell J, Barclay E, Wortham NC, Hunt T, Mitchell M, Olpin S, Moat SJ, et al. 2005. Accumulation of Krebs cycle intermediates and over-expression of HIF1α in tumours which result from germline FH and SDH mutations. Hum Mol Genet 14: 2231-2239.
39. Rose NR, McDonough MA, King ON, Kawamura A, Schofield CJ. 2011. Inhibition of 2-oxoglutarate dependent oxygenases. Chem Soc Rev 40: 4364-4397.
40. Scatena R, Bottoni P, Giorgia Botta G, Martorana GE, Giardina B. 2007. The role of mitochondria in pharmacotoxicology: A reevaluation of an old, newly emerging topic. Am J Physiol Cell Physiol 293: C12-C21. doi: 10.1152/ajpcell.00314.2006.
41. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, Pan Y, Simon MC, Thompson CB, Gottlieb E. 2005. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase. Cancer Cell 7: 77-85.
42. Taguchi K, Motohashi H, Yamamoto M. 2011. Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells 16: 123-140.
43. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L, et al. 2009. Conversion of 5-methylcytosine to 5-hydroxymethyl-cytosine in mammalian DNA by MLL partner TET1. Science 324: 930-935.
44. Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, Leigh I, Gorman P, Lamlum H, Rahman S, et al. 2002. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 30: 406-410.
45. Tsukada Y, Fang J, Erdjument-Bromage H, Warren ME, Borchers CH, Tempst P, Zhang Y. 2006. Histone demethylation by a family of JmjC domain-containing proteins. Nature 439: 811-816.
46. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Wang P, Xiao MT, et al. 2011. Oncometabolite 2-hydroxy-glutarate is a competitive inhibitor of α-ketoglutarate-de-pendent dioxygenases. Cancer Cell 19: 17-30.
47. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, et al. 2009. IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765-773.
48. Yu F, White SB, Zhao Q, Lee FS. 2001. HIF-1α binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc Natl Acad Sci 98: 9630-9635.
49. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, Yu W, Li Z, Gong L, Peng Y, et al. 2009. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1α. Science 324: 261-265.